SGMOQ — Sangamo Therapeutics Share Price
Last trade - 00:00- $47.64m
- $20.06m
- $39.55m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 1.38 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -1808.77% | ||
| Return on Equity | n/a | ||
| Operating Margin | -357.55% | ||
Financial Summary
| Year End 31st Dec | Unit | 2021 | 2022 | 2023 | 2024 | 2025 | 2026E | 2027E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 110.7 | 111.3 | 176.23 | 57.8 | 39.55 | 9.9 | 70.8 | -19.66% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Sangamo Therapeutics, Inc. is a genomic medicine company that pioneered the development of zinc finger and capsid delivery technologies to address serious neurological and rare diseases. The Company's assets include clinical-stage programs ST-503 for chronic neuropathic pain and giroctocogene fitelparvovec for hemophilia A, as well as its cell therapy and regulatory T cell (T-Reg) assets. The Company is developing ST-503, an investigational epigenetic regulator for the treatment of intractable pain due to small fiber neuropathy (SFN), a type of chronic neuropathic pain. ST-503 uses an AAV vector carrying an engineered zinc finger repressor (ZFR) to specifically target the human gene, SCN9A, that encodes the Nav1.7 sodium channel and is critical for pain signaling. Giroctocogene fitelparvovec is a liver-tropic rAAV6 vector carrying a B-domain deleted F8 gene that is delivered through a single IV infusion. The Company is operating under court supervision in Chapter 11.
Directors
- H. Stewart Parker NEC (65)
- Alexander Macrae PRE (58)
- Prathyusha Duraibabu CFO (43)
- D. Mark McClung EVP (58)
- R. Andrew Ramelmeier EVP (59)
- Jason Fontenot SVP (51)
- Robert Schott SVP (63)
- Robert Carey IND (63)
- Kenneth Hillan IND (60)
- John Markels IND (55)
- James Meyers IND (56)
- Saira Ramasastry IND (45)
- Karen Smith IND (53)
- Joseph Zakrzewski IND
- Last Annual
- December 31st, 2025
- Last Interim
- March 31st, 2026
- Incorporated
- June 22nd, 1995
- Public Since
- April 6th, 2000
- No. of Shareholders
- 49
- No. of Employees
- 142
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 414,288,847
- Address
- 501 Canal Blvd, RICHMOND, 94804
- Web
- https://www.sangamo.com
- Phone
- +1 5109706000
- Auditors
- Ernst & Young LLP
Latest News for SGMOQ
Upcoming Events for SGMOQ
Q3 2026 Sangamo Therapeutics Inc Earnings Release
Q4 2026 Sangamo Therapeutics Inc Earnings Release
Similar to SGMOQ
ABPRO Holdings
Pink Sheets on Nasdaq
Actavia Life Sciences
Pink Sheets on Nasdaq
Acura Pharmaceuticals
Pink Sheets on Nasdaq
Adaptin Bio
Pink Sheets on Nasdaq
Adhera Therapeutics
Pink Sheets on Nasdaq
FAQ
As of Today at 23:06 UTC, shares in Sangamo Therapeutics are trading at $0.12. This share price information is delayed by 15 minutes.
Shares in Sangamo Therapeutics last closed at $0.12 and the price had moved by -82.49% over the past 365 days. In terms of relative price strength the Sangamo Therapeutics share price has underperformed the S&P500 Index by -84.33% over the past year.
The overall consensus recommendation for Sangamo Therapeutics is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreSangamo Therapeutics does not currently pay a dividend.
Sangamo Therapeutics does not currently pay a dividend.
Sangamo Therapeutics does not currently pay a dividend.
To buy shares in Sangamo Therapeutics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.12, shares in Sangamo Therapeutics had a market capitalisation of $47.64m.
Here are the trading details for Sangamo Therapeutics:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: SGMOQ
Based on an overall assessment of its quality, value and momentum Sangamo Therapeutics is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Sangamo Therapeutics is $1.25. That is 986.96% above the last closing price of $0.12.
Analysts covering Sangamo Therapeutics currently have a consensus Earnings Per Share (EPS) forecast of -$0.30 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Sangamo Therapeutics. Over the past six months, its share price has underperformed the S&P500 Index by -41.73%.
As of the last closing price of $0.12, shares in Sangamo Therapeutics were trading -47.16% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Sangamo Therapeutics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.12.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Sangamo Therapeutics' management team is headed by:
- H. Stewart Parker - NEC
- Alexander Macrae - PRE
- Prathyusha Duraibabu - CFO
- D. Mark McClung - EVP
- R. Andrew Ramelmeier - EVP
- Jason Fontenot - SVP
- Robert Schott - SVP
- Robert Carey - IND
- Kenneth Hillan - IND
- John Markels - IND
- James Meyers - IND
- Saira Ramasastry - IND
- Karen Smith - IND
- Joseph Zakrzewski - IND